Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 101Gastrointestinal 23CNS 18Breast 17Genitourinary 14Dermatologic 12Gynecologic 9Head & Neck 7Sarcoma 6Lymphoid 5Plasma cell 2Other hematologic neoplasm 2Endocrine 2NET 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 13Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Follicular 8Myelodysplastic Syndromes 7Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Biphenotypic, Acute 5Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Mycosis Fungoides 3Melanoma 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Chronic 3Immunoblastic Lymphadenopathy 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2

Interventions

Gemcitabine 3sargramostim 2pertuzumab 2binimetinib 2Trastuzumab 2Specimen Handling 2Polymerase Chain Reaction 2Paclitaxel 2Nicotine 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Counseling 2Bupropion 2Azacitidine 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1motesanib diphosphate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Magnetic Resonance Spectroscopy × Other hematologic neoplasm × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡